NanoString Tech rallies on expanded availability for breast cancer diagnostic test

|About: NanoString Technologies (NSTG)|By:, SA News Editor

NanoString Technologies (NSTG +16.2%) is enjoying a strong session after announcing that the Prosigna Breast Cancer Prognostic Gene Signature Assay will be available nationwide in Q1 2014.

LH and DGX have "chosen to add the Prosigna Assay to their comprehensive suites of breast cancer diagnostic tests," NSTG notes. (PR)

Meanwhile, Baird is out with an upgrade to Outperform from Neutral. Price target is now $18 (from $12).